Quarterly report · Q1
2269.TEDINET S100OXYQ
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥247.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥1.01T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥235.9bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥18.0bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥18.6bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥18.4bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥94.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥19.1bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥23.2bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥19.1bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥16.0bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥87.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.5bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥16.2bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥13.2bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥1.14T | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥1.12T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.10T | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥419.0bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥404.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥725.4bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥713.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥663.8bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥87.8bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥67.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥84.9bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥68.1bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥127.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.2bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.0bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥22.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥77.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥36.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥113.73 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥607.24 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.09 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 60.0% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.2% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥140m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥140m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥278m |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥204.4bn |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥204.3bn |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥131m |
| jpcrp040300-q1r_E21902-000Foodreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥14.5bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥42.9bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥42.9bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥9m |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥247.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥247.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥140m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥18.3bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥206m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥206m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥163m |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥199.9bn |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥199.8bn |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥124m |
| jpcrp040300-q1r_E21902-000Foodreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥19.4bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥36.2bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥36.2bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥81m |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥638m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥236.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥235.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥206m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥18.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 512
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |